Evidence map›Paper›PMID 35941690›Full record

ArticleJournal of experimental & clinical cancer research : CR2022

Suppression of VEGFD expression by S-nitrosylation promotes the development of lung adenocarcinoma.

Qiangqiang He, Meiyu Qu, Tingyu Shen, Yana Xu, Jiahao Luo, Dan Tan, Chengyun Xu, Muhammad Qasim Barkat, Ling-Hui Zeng, Ximei Wu

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Qiangqiang He *Department of Pharmacology, Zhejiang University School of Medicine, 866 Yuhangtang Road, 310058, Hangzhou, China.
Meiyu Qu *Department of Pharmacology, Zhejiang University School of Medicine, 866 Yuhangtang Road, 310058, Hangzhou, China.
Tingyu ShenDepartment of Pharmacology, Zhejiang University School of Medicine, 866 Yuhangtang Road, 310058, Hangzhou, China.
Yana XuDepartment of Pharmacology, Zhejiang University School of Medicine, 866 Yuhangtang Road, 310058, Hangzhou, China.
Jiahao LuoDepartment of Pharmacology, Zhejiang University School of Medicine, 866 Yuhangtang Road, 310058, Hangzhou, China.
Dan TanDepartment of Pharmacology, Zhejiang University School of Medicine, 866 Yuhangtang Road, 310058, Hangzhou, China.
Chengyun XuDepartment of Pharmacology, Zhejiang University School of Medicine, 866 Yuhangtang Road, 310058, Hangzhou, China.
Muhammad Qasim BarkatDepartment of Pharmacology, Zhejiang University School of Medicine, 866 Yuhangtang Road, 310058, Hangzhou, China.
Ling-Hui ZengDepartment of Pharmacology, Zhejiang University City College, 51 Huzhou Street, 310015, Hangzhou, China. zenglh@zucc.edu.cn.
Ximei WuDepartment of Pharmacology, Zhejiang University School of Medicine, 866 Yuhangtang Road, 310058, Hangzhou, China. xiwu@zju.edu.cn.ORCID http://orcid.org/0000-0002-3316-893X
Zhejiang University · CNHuzhou University · CNSir Run Run Shaw Hospital · CN

Funding

National Natural Science Foundation of China Nos. 31571493, 81741043, 31871395, and 32170841
6 · The paper itself

Abstract

backgroundVascular endothelial growth factor D (VEGFD), a member of the VEGF family, is implicated in angiogenesis and lymphangiogenesis, and is deemed to be expressed at a low level in cancers. S-nitrosylation, a NO (nitric oxide)-mediated post-translational modification has a critical role in angiogenesis. Here, we attempt to dissect the role and underlying mechanism of S-nitrosylation-mediated VEGFD suppression in lung adenocarcinoma (LUAD).

methodsMessenger RNA and protein expression of VEGFD in LUAD were analyzed by TCGA and CPTAC database, respectively, and Assistant for Clinical Bioinformatics was performed for complex analysis. Mouse models with urethane (Ure)-induced LUAD or LUAD xenograft were established to investigate the role of S-nitrosylation in VEGFD expression and of VEGFD mutants in the oncogenesis of LUAD. Molecular, cellular, and biochemical approaches were applied to explore the underlying mechanism of S-nitrosylation-mediated VEGFD suppression. Tube formation and wound healing assays were used to examine the role of VEGFD on the angiogenesis and migration of LUAD cells, and the molecular modeling was applied to predict the protein stability of VEGFD mutant.

resultsVEGFD mRNA and protein levels were decreased to a different extent in multiple primary malignancies, especially in LUAD. Low VEGFD protein expression was closely related to the oncogenesis of LUAD and resultant from excessive NO-induced VEGFD S-nitrosylation at Cys277. Moreover, inhibition of S-nitrosoglutathione reductase consistently decreased the VEGFD denitrosylation at Cys277 and consequently promoted angiogenesis of LUAD. Finally, the VEGFD

conclusionLow-expression of VEGFD positively correlates with LUAD development. Aberrant S-nitrosylation of VEGFD negates itself to induce the tumorigenesis of LUAD, whereas normal S-nitrosylation of VEGFD is indispensable for its secretion and repression of angiogenesis of LUAD.

Indexed as

Adenocarcinoma of LungLung NeoplasmsAnimalsCarcinogenesisHumansMiceNitric OxideVascular Endothelial Growth Factor DNitric OxideVascular Endothelial Growth Factor DVEGFD protein, humanAngiogenesisGSNORLung adenocarcinomaS-nitrosylationVEGFAVEGFD

Identifiers

PMID35941690
PMCPMC9358865
OpenAlexW4290565574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.